A Study of Mircera for the Treatment of Anemia in Dialysis Patients
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of Mircera given intravenously in the
treatment of renal anemia in chronic kidney disease patients on dialysis who are not
currently receiving epoetin or any other erythropoietic substance. The anticipated time on
study treatment is 1-2 years and the target sample size is 100-500 individuals.